This phase Ib/II trial studies the side effects and how well stereotactic body radiation
therapy and durvalumab with or without tremelimumab before surgery work in treating
participants with human papillomavirus positive oropharyngeal squamous cell cancer.
Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays
directly to the tumor using smaller doses over several days and may cause less damage to
normal tissue. Monoclonal antibodies, such as durvalumab and tremelimumab, may interfere with
the ability of tumor cells to grow and spread. Giving stereotactic body radiation therapy and
durvalumab with or without tremelimumab before surgery may work better in treating
participants with oropharyngeal squamous cell cancer.
PRIMARY OBJECTIVES:
I. To determine the safety and tolerability associated with the following treatment regimens:
Cohort 1: stereotactic body radiation therapy (SBRT) and durvalumab, followed by transoral
robotic surgery (TORS) and adjuvant durvalumab and cohort 2: SBRT and durvalumab +
tremelimumab, followed by TORS and adjuvant durvalumab. (Phase I safety lead-in) II. To
assess the efficacy of the treatment combination deemed safe from Phase I in terms of
progression free survival, in order to determine the non-inferiority of tumor control
(progression-free survival [PFS] of 85% at 2 years) compared to conventional large field
adjuvant radiotherapy +/- concurrent chemotherapy. (Phase II) III. To determine Common
Terminology Criteria for Adverse Events (CTCAE) grade 3+ acute and chronic toxicities at the
end of radiation, after surgery, at the end of adjuvant immunotherapy infusion, at 3 month,
at 6 month, at 1 year, and at 2 years. (Phase II)
SECONDARY OBJECTIVES:
I. To determine the objective response rate to durvalumab +/- tremelimumab + SBRT prior to
TORS.
II. To determine the rate of subclinical lymph node involvement at time of TORS and neck
dissection.
III. To determine the rate of contra-lateral neck failure with medial oropharyngeal and base
of tongue primary lesions.
IV. To determine the potential salvage rate. V. To determine the locoregional control,
distant control, and overall survival.
VI. To determine the incidence of all toxicity associated with treatment protocol.
VII. To determine the short- and long-term quality of life of patients on protocol.
TRANSLATIONAL OBJECTIVES:
I. To evaluate the impact of KRAS gene-variant mutation on immune response and treatment
outcome.
II. To evaluate the impact of PI3K gene mutation on immune response and treatment outcome.
III. Saliva samples to evaluate biomarkers for immune response to human papillomavirus (HPV)
associated oropharyngeal squamous cell carcinoma (OPSCC) to be collected prior to treatment,
at time of TORS, and at each yearly follow-up visit.
IV. Blood samples to evaluate biomarkers of immune response to HPV associated OPSCC to be
collected prior to treatment, at time of TORS, and at each yearly follow-up visit.
V. Tumor tissue taken at the time of initial biopsy and at time of resection will be profiled
for tumor infiltrating lymphocytes; activation markers and antigen specific T-cell receptor
(TCR) utilization/diversity will be evaluated for additional checkpoint targets.
VI. On long-term follow-up, tumor antigen specific T lymphocyte memory populations will be
monitored for representation and robustness in in-vitro stimulation assays as potential
biomarker of continued anti-tumor activity.
VII. Immortalization of tumor infiltrating B-cells for identification of antigen presenting
complex, antibody specificity, and potential serologic markers of continuing long-term immune
response in patients.
OUTLINE: Participants are assigned to 1 or 2 cohorts.
COHORT I: Beginning day 0 of course 1, participants undergo stereotactic body radiation
therapy 5 days a week for 1 week and receive durvalumab intravenously (IV) over 1 hour on
days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants
then undergo transoral robotic surgery and modified radical neck dissection between weeks
6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks.
Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or
unacceptable toxicity.
COHORT II: Beginning day 0 of course 1, participants undergo stereotactic body radiation
therapy 5 days a week for 1 week and receive tremelimumab IV and durvalumab IV over 1 hour on
days 0 and 27 in the absence of disease progression or unacceptable toxicity. Participants
then undergo transoral robotic surgery and modified radical neck dissection between weeks
6-8. Beginning week 12, participants then receive durvalumab IV over 1 hour every 4 weeks.
Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or
unacceptable toxicity.
After completion of study treatment, participants are followed up every 12 weeks for 2 years
and then periodically thereafter.
Inclusion Criteria:
- Written informed consent from the patient/legal representative prior to performing any
protocol-related procedures, including screening evaluation.
- Pathologically proven diagnosis of HPV-positive squamous cell carcinoma of the
oropharynx. HPV-positivity will be defined as tumors that are p16-positive by
immunohistochemistry.
- Patients must have T0-3 disease with all gross disease amenable to R0 resection
(reviewed by multidisciplinary study team) and is eligible for TORS in the opinion of
the treating physician.
- N0-N2b with all cervical disease confined to 2 cervical lymph node levels if the
involved nodal levels are adjacent.
- Karnofsky performance status >= 70.
- Body weight >= 50 kg.
- Patients who are medically operable, without pre-existing medical conditions that
could inhibit surgery following neoadjuvant therapy, and do not refuse surgery.
- Patients with smoking history (< 20 pack year history) is allowed.
- Patients must have MRI neck with and without contrast and a diagnostic positron
emission tomography (PET), computed tomography (CT) or PET/CT skull base to mid-thigh
with contrast within 30 days prior to SBRT.
- Hemoglobin >= 9.0 g/dL.
- Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3).
- Platelet count >= 100 (or 75) x 10^9/L (>= 75,000 per mm^3).
- Serum bilirubin =< 1.5 x institutional upper limit of normal (ULN). This will not
apply to subjects with confirmed Gilbert?s syndrome (persistent or recurrent
hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or
hepatic pathology), who will be allowed only in consultation with their physician.
- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional
upper limit of normal.
- Serum creatinine > 40 mL/min.
- Female patients with reproductive potential (e.g., females menopausal for less than 1
year and not surgically sterilized) must agree to practice two highly effective
contraceptive measures for the duration of study drug therapy and for at least 90 days
after completion of durvalumab monotherapy or for at least 180 days after completion
of durvalumab/tremelimumab combination therapy. Female patients of childbearing
potential must provide a negative pregnancy test (urine) prior to treatment
initiation. Male patients, whose partners are women with reproductive potential, and
the women themselves also must agree to practice two effective contraceptive measures.
- Female patients with evidence of post-menopausal status if they have been amenorrheic
for 12 months without an alternative medical cause. The following age-specific
requirements apply:
- Women < 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle-stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy).
- Women >= 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced menopause with last menses > 1 year.
- Subject is willing and able to comply with the protocol for the duration of the study
including undergoing treatment and scheduled visits and examinations including follow
up.
Exclusion Criteria:
- Karnofsky performance status (KPS) < 70.
- Body weight < 50 kg.
- Histology other than squamous cell carcinoma.
- Primary site other than oropharynx (i.e. oral cavity, salivary glands, nasal cavity,
paranasal sinuses, larynx, or nasopharynx) or of unknown primary.
- Patients with synchronous or bilateral disease.
- Patient with N3 nodal disease, N2c nodal disease, and N2b disease with gross disease
in more than 2 neck levels (levels not adjacent to each others are also not allowed).
- Patients with recurrent head and neck cancer.
- Patients with metastatic disease on initial staging study.
- Patients who underwent attempted resection rather than the diagnostic biopsy of the
primary site or nodal sampling of the neck disease.
- Prior systemic therapy (chemotherapy, biologic, or immunotherapy) for the same OPSCC.
- Previous treatment with Anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4)
including tremelimumab or PD1/PD-L1 inhibitor (programmed cell death) , including
durvalumab.
- Concurrent enrollment in another clinical trial.
- Patients that received prior radiotherapy that would result in overlap of radiation
therapy fields.
- History of another primary malignancy except for:
- Malignancy treated with curative intent and with no evidence of active disease >=
5 years before the first dose of study drug and of low potential risk for
recurrence
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
of disease
- Adequately treated carcinoma in situ without evidence of disease.
- Any concurrent anticancer therapy.
- Mean QT interval corrected for heart rate (QTc) >= 470 ms calculated from a baseline
electrocardiogram using Fredericia?s correction.
- Current or prior use of immunosuppressive medication within 14 days before the first
dose of durvalumab or tremelimumab, with the exceptions of intranasal and inhaled
corticosteroids or systemic corticosteroids at physiological doses, which are not to
exceed 10 mg/day of prednisone, or an equivalent corticosteroid.
- Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
criterion:
- Patients with vitiligo or alopecia
- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement
- Any chronic skin condition that does not require systemic therapy
- Patients without active disease in the last 5 years may be included but only
after consultation with the study physician
- Patients with celiac disease controlled by diet alone.
- History of allogeneic organ transplant.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, seizures, symptomatic congestive heart failure, uncontrolled hypertension,
unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, active peptic
ulcer disease or gastritis, serious chronic gastrointestinal (GI) conditions
associated with diarrhea, active bleeding diatheses including any subject known to
have evidence of acute or chronic hepatitis B, hepatitis C or human immunodeficiency
virus (HIV), or psychiatric illness/social situations that would limit compliance with
study requirements or compromise the ability of the subject to give written informed
consent.
- Receipt of live attenuated vaccination within 30 days prior to study entry or within
30 days of receiving durvalumab or tremelimumab.
- Female patients who are pregnant or breastfeeding or male or female patients of
reproductive potential who are not willing to employ two highly effective birth
control methods from screening to 90 days after the last dose of durvalumab
monotherapy or 180 days after the last dose of durvalumab + tremelimumab combination
therapy.
- Major surgical procedure (as defined by the investigator) within 28 days prior to the
first dose of investigational product (IP). Note: Local surgery of isolated lesions
for palliative intent is acceptable.
- Any unresolved toxicity National Cancer Institute (NCI) CTCAE grade >= 2 from previous
anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values
defined in the inclusion criteria
- Patients with grade >= 2 neuropathy will be evaluated on a case-by-case basis
after consultation with the study physician.
- Patients with irreversible toxicity not reasonably expected to be exacerbated by
treatment with durvalumab or tremelimumab may be included only after consultation
with the study physician.
- Any condition that, in the opinion of the investigator, would interfere with
evaluation of study treatment or interpretation of patient safety or study results.
- Known allergy or hypersensitivity to IP or any excipient.
- Subjects with uncontrolled seizures.
- History of leptomeningeal carcinomatosis.
- History of active primary immunodeficiency.
- Clinical documentation of active infection including tuberculosis (clinical evaluation
that includes clinical history, physical examination and radiographic findings, and
tuberculosis (TB) testing in line with local practice), hepatitis B (known positive
hepatitis B virus [HBV] surface antigen (HBsAg) result), hepatitis C, or human
immunodeficiency virus (positive HIV 1/2 antibodies). Patients with a past or resolved
HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and
absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are
eligible only if polymerase chain reaction is negative for HCV ribonucleic acid (RNA).
